Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 0.44 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | KCNT1 | Q5JUK3 | 9/20 | 0.38 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | KCNMB1 | Q16558 | 1/20 | 0.37 |
| ▸ | KCNT2 | Q6UVM3 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL454322 | 0.85 | DGAT2 (0.40) | ABL1DGAT2RIPK1KCNT1KCNQ1 | |
| SCHEMBL15450837 | 0.83 | DGAT2 (0.40) | ABL1DGAT2RIPK1KCNT1KCNQ1 | |
| SCHEMBL456434 | 0.81 | DGAT2 (0.38) | DGAT2RIPK1KCNT1KCNQ1KCNH2 | |
| SCHEMBL456082 | 0.78 | ABL1 (0.46) | ABL1ROCK2 | |
| SCHEMBL452909 | 0.78 | ABL1 (0.49) | ABL1SMN1; SMN2 | |
| SCHEMBL452218 | 0.77 | RAB9A (0.39) | DGAT2RIPK1KCNT1KCNQ1KCNH2 | |
| SCHEMBL2260839 | 0.76 | RIPK1 (0.43) | DGAT2RIPK1KCNT1KCNQ1KCNH2 | |
| SCHEMBL2260453 | 0.74 | CTSA (0.47) | DGAT2RIPK1ROCK2ROCK1 | |
| SCHEMBL454067 | 0.73 | GRIN1 (0.40) | DGAT2RIPK1KCNT1KCNQ1KCNH2 | |
| SCHEMBL2265558 | 0.73 | RIPK1 (0.41) | DGAT2RIPK1KCNT1KCNQ1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238647-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2016-01-19 | — | — | US | disclosed |
| US-9238647-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2016-01-19 | — | — | US | disclosed |
| EP-2410857-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2014-01-29 | — | — | EP | disclosed |
| EP-2410857-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2014-01-29 | — | — | EP | disclosed |
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | P2RX3, P2RX1, P2RX2 | ABL1 3212/4885DGAT2 3948/4885RIPK1 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.